← Leaderboards
Richard T Libby
Jackson Laboratory
$7,082,346
Attributed
$10,498,300
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,498,300 · 4
By mechanism
R01$10,392,044 · 3
F32$106,256 · 1
Top collaborators
- Gareth R Howell9 shared
- Simon W John4 shared
Most similar at Jackson Laboratory
Same institution · by research overlap
- Gareth R Howell$50,118,570
- Ruth Anne Eatock$10,098,189
- Peter Gerard Fuerst$1,620,598
- John C Schimenti$25,146,012
Others in their field
Top investigators on “Glaucoma”
- Rohit Varma · University Of Southern California$58,233,961
- Janey L Wiggs · Massachusetts Eye And Ear Infirmary$36,083,461
- Cecilia Sungmin Lee · University Of Washington$32,086,169
- David Huang · Cleveland Clinic Lerner Col/Med-Cwru$27,740,623
- Linda M Zangwill · University Of California San Diego$23,025,291
- Robert N Weinreb · University Of California, San Diego$21,784,031
Research focus
GlaucomaCellsPlayCell DeathRetinaRetinal Ganglion CellsBlindnessNerve DegenerationMolecularOcular HypertensionPreventResponseSignal TransductionCause Of DeathNeuronsPathway InteractionsOutputSignal PathwayGenesCessation Of LifeOptic NervePredispositionInjuryPrevention
Grant awards (26)
Dissecting the complex role of microglia states in glaucoma$650,978
R01 · FY2025 · EY · contact PI
Dissecting the complex role of microglia states in glaucoma$644,506
R01 · FY2024 · EY · contact PI
Dissecting the complex role of microglia states in glaucoma$650,498
R01 · FY2023 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$570,843
R01 · FY2023 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$553,716
R01 · FY2022 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$553,716
R01 · FY2021 · EY · contact PI
Cell specific roles of the endothelin system in glaucoma-relevant retinal ganglion cell death$502,883
R01 · FY2021 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$539,665
R01 · FY2020 · EY · contact PI
Cell specific roles of the endothelin system in glaucoma-relevant retinal ganglion cell death$518,435
R01 · FY2020 · EY · contact PI
Cell specific roles of the endothelin system in glaucoma-relevant retinal ganglion cell death$545,801
R01 · FY2019 · EY · contact PI
Cell specific roles of the endothelin system in glaucoma-relevant retinal ganglion cell death$518,435
R01 · FY2018 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$345,375
R01 · FY2018 · EY · contact PI
Cell specific roles of the endothelin system in glaucoma-relevant retinal ganglion cell death$50,802
R01 · FY2018 · EY · contact PI
Cell specific roles of the endothelin system in glaucoma-relevant retinal ganglion cell death$531,631
R01 · FY2017 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$345,375
R01 · FY2017 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$345,375
R01 · FY2016 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$338,467
R01 · FY2015 · EY · contact PI
Cell Death Pathways in Glaucomatous Neurodegeneration$345,375
R01 · FY2014 · EY · contact PI
Cell death pathways in glaucomatous neurodegeneration$329,314
R01 · FY2012 · EY · contact PI
Cell death pathways in glaucomatous neurodegeneration$329,314
R01 · FY2011 · EY · contact PI
Cell death pathways in glaucomatous neurodegeneration$343,035
R01 · FY2010 · EY · contact PI
Cell death pathways in glaucomatous neurodegeneration$346,500
R01 · FY2009 · EY · contact PI
Cell death pathways in glaucomatous neurodegeneration$145,505
R01 · FY2009 · EY · contact PI
Cell death pathways in glaucomatous neurodegeneration$346,500
R01 · FY2008 · EY · contact PI
Testing therapeutic pathways in genetic glaucoma$54,352
F32 · FY2004 · EY
Testing therapeutic pathways in genetic glaucoma$51,904
F32 · FY2003 · EY